Abstract
We read with interest the article in this issue of the Journal by
Wang et al. (1), whose study evaluated the association between
smoking exposure and treatment response, progression-free
survival, and overall survival in patients with advanced nonsmall cell lung cancer treated with immune checkpoint inhibitor
(ICI) monotherapy. The authors provided quantitative evidence
that smoking pack-years of tobacco was independently prognostic above clinicopathological characteristics, tumor mutation
burden, and PD-L1 expression for response and survival outcomes within a cohort of 644 patients. In this correspondence,
we highlight 2 aspects that require further comment: 1) the
authors statements on the potential for smoking exposure to
inform ICI efficacy, in the absence of a control arm, and 2) the
potential importance of smoking pack-years vs smoking status
(ie, never, former, or current) to future research.
Wang et al. (1), whose study evaluated the association between
smoking exposure and treatment response, progression-free
survival, and overall survival in patients with advanced nonsmall cell lung cancer treated with immune checkpoint inhibitor
(ICI) monotherapy. The authors provided quantitative evidence
that smoking pack-years of tobacco was independently prognostic above clinicopathological characteristics, tumor mutation
burden, and PD-L1 expression for response and survival outcomes within a cohort of 644 patients. In this correspondence,
we highlight 2 aspects that require further comment: 1) the
authors statements on the potential for smoking exposure to
inform ICI efficacy, in the absence of a control arm, and 2) the
potential importance of smoking pack-years vs smoking status
(ie, never, former, or current) to future research.
| Original language | English |
|---|---|
| Pages (from-to) | 475-476 |
| Number of pages | 2 |
| Journal | Journal of the National Cancer Institute |
| Volume | 114 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2022 |
Keywords
- Smoking History
- Immune Checkpoint Inhibitor
- Lung Cancer